Intensive multimodal therapy is effective for orbital retinoblastoma
March 17th 2022Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.
Apellis announces longer-term data from Phase 3 DERBY and OAKS studies for geographic atrophy
March 16th 2022According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over.
Glaukos announces start of Phase II corneal health clinical program for pharmaceutical platform
March 14th 2022The company’s iLink therapy for the treatment of keratoconus consists of novel single-use drug formulations that are bio-activated by proprietary systems through the delivery of ultraviolet light to the cornea to induce corneal cross-linking designed to strengthen, stabilize and reshape the cornea.